Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1977 May;59(5):951–958. doi: 10.1172/JCI108717

Suppression of immune complex-induced inflammation by the chemotactic factor inactivator.

K J Johnson, T P Anderson, P A Ward
PMCID: PMC372303  PMID: 140184

Abstract

Small amounts (10(-10) mol) of purified human chemotactic factor inactivator (CFI) suppress leukocytic infiltration, permeability changes, and hemorrhage associated with acute immune complex-induced injury in rats. The reversed passive dermal Arthus reaction and acute immune complex-induced alveolitis in rats have served as the model systems of inflammation. The mechanism of inhibition does not appear to relate to interference with formation and deposition of immune complexes, or with fixation of complement in vitro or iv vivo. Human CFI inhibits in vitro the chemotactic activity generated in complement-activated rat serum. The inhibitory effects of human CFI are not seen if it is first heat inactivated. The data provide the first direct support for the conclusion that CFI has anti-inflammatory activity.

Full text

PDF
951

Images in this article

954Image
on p.954
955Image
on p.955
956Image
on p.956

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berenberg J. L., Ward P. A. Chemotactic factor inactivator in normal human serum. J Clin Invest. 1973 May;52(5):1200–1206. doi: 10.1172/JCI107287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. COCHRANE C. G., WEIGLE W. O., DIXON F. J. The role of polymorphonuclear leukocytes in the initiation and cessation of the Arthus vasculitis. J Exp Med. 1959 Sep 1;110:481–494. doi: 10.1084/jem.110.3.481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chapman W. E., Ward P. A. Changes in C3 metabolism during protozoan infection (Babesia rodhaini) in rats. J Immunol. 1976 May;116(5):1284–1288. [PubMed] [Google Scholar]
  4. Cochrane C. G. Immunologic tissue injury mediated by neutrophilic leukocytes. Adv Immunol. 1968;9:97–162. doi: 10.1016/s0065-2776(08)60442-3. [DOI] [PubMed] [Google Scholar]
  5. Johnson K. J., Ward P. A. Acute immunologic pulmonary alveolitis. J Clin Invest. 1974 Aug;54(2):349–357. doi: 10.1172/JCI107770. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Maderazo E. C., Ward P. A., Quintiliani R. Defective regulation of chemotaxis in cirrhosis. J Lab Clin Med. 1975 Apr;85(4):621–630. [PubMed] [Google Scholar]
  7. Maderazo E. G., Ward P. A., Woronick C. L., Kubik J., DeGraff A. C., Jr Leukotactic dystunction in sarcoidosis. Ann Intern Med. 1976 Apr;84(4):414–419. doi: 10.7326/0003-4819-84-4-414. [DOI] [PubMed] [Google Scholar]
  8. Till G., Ward P. A. Two distinct chemotactic factor inactivators in human serum. J Immunol. 1975 Feb;114(2 Pt 2):843–847. [PubMed] [Google Scholar]
  9. Van Epps D. E., Palmer D. L., Williams R. C., Jr Characterization of serum inhibitors of neutrophil chemotaxis associated with anergy. J Immunol. 1974 Jul;113(1):189–200. [PubMed] [Google Scholar]
  10. WARD P. A., COCHRANE C. G. BOUND COMPLEMENT AND IMMUNOLOGIC INJURY OF BLOOD VESSELS. J Exp Med. 1965 Feb 1;121:215–234. doi: 10.1084/jem.121.2.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ward P. A., Berenberg J. L. Defective regulation of inflammatory mediators in Hodgkin's disease. Supernormal levels of chemotactic-factor inactivator. N Engl J Med. 1974 Jan 10;290(2):76–80. doi: 10.1056/NEJM197401102900203. [DOI] [PubMed] [Google Scholar]
  12. Ward P. A., Goralnick S., Bullock W. E. Defective leukotaxis in patients with lepromatous leprosy. J Lab Clin Med. 1976 Jun;87(6):1025–1032. [PubMed] [Google Scholar]
  13. Ward P. A., Hill J. H. Biologic role of complement products. Complement-derived leukotactic activity extractable from lesions of immunologic vasculitis. J Immunol. 1972 May;108(5):1137–1145. [PubMed] [Google Scholar]
  14. Ward P. A., Hill J. H. C5 chemotactic fragments produced by an enzyme in lysosomal granules of neutrophils. J Immunol. 1970 Mar;104(3):535–543. [PubMed] [Google Scholar]
  15. Ward P. A., Ozols J. Characterization of the protease activity in the chemotactic factor inactivator. J Clin Invest. 1976 Jul;58(1):123–129. doi: 10.1172/JCI108440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Ward P. A. The chemosuppression of chemotaxis. J Exp Med. 1966 Aug 1;124(2):209–226. doi: 10.1084/jem.124.2.209. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES